Urinary proteome
Introduction
Factors that lead to atherosclerosis can exert systemic effects, including impaired kidney function, potentially creating distinct urine protein signatures prognostic of cardiovascular disease (CVD) risk. Urine possesses several attractive features for biomarker discovery and assessment of disease, including CVD, as it is readily available, can be collected non-invasively, and enables monitoring of a wide range of physiological processes.
The aims of this project were as follows:
- To determine the number of proteins detectable in urine
- To explore the relationship between the urinary proteome and risk of secondary CVD events in individuals with stable coronary heart disease (CHD)
- To identify proteins in urine that may reveal new biological pathways and systems underlying CVD risk
- To compare the prognostic performance of protein biomarkers in urine and in plasma in predicting CVD events
Methods Overview
- 24 h urine samples were assayed for proteins from 818 participants in the observational Heart & Soul cohort of outpatients with stable CHD, collected at study baseline (Beatty et al. J Am Heart Assoc: 4(7): e001646).
- Follow-up > 11-y.
- Kidney function ranged from normal to moderately impaired.
- A total of 4,316 proteins were measured using SomaScan®, a high-throughput assay that uses modified aptamers as binding reagents.
- A protein-based normalization was performed.
- Urine proteins were analyzed for their association with the CVD outcome (defined as myocardial infarction, stroke, heart failure or death) and CVD risk prediction models were constructed using the LASSO method and backwards selection.
Conclusion
A 4-y CVD risk prediction model based on urinary proteins performs similarly to a model based on plasma, suggesting the potential clinical utility of urine as a matrix for early CVD detection.
Download this poster to learn more
More posters
PosterOptimizing biomarker discovery with focus on low coefficient of variation in large-scale proteomics
Coefficients of variation (CV) describe innate technical variation in high throughput molecular measurement platforms and are a standard metric for characterizing and monitoring assay precision. Median CVs range from ~4.5% to 18.0% for immunoassay technology, 1 up to >30% for mass spectrometry,2 ~5% for the SomaScan® Assay, and ~10% for the Olink Explore Assay (Figure 1). Large CVs can cause technical variability to overwhelm biological signal.
PosterA proteomic predictor of conversion from mild cognitive impairment to dementia with potential utility in enhancing productivity of emerging clinical trials
A significant proportion of individuals with mild cognitive impairment (MCI) develop dementia, with annual conversion rates exceeding 10%. Earlier dementia diagnosis and intervention can improve outcomes, and new disease-modifying drugs are being repositioned for the preclinical stages of illness.
PosterComparison of Proteomic CV Risk to Established ASCVD 10-Year Risk Decision Points
The ASCVD pooled cohort equation (PCE) is well-established for CV risk assessment. Decision points for determining treatment plans are low, intermediate and high risk over 10 years, however this approach over and underestimates risk in certain subgroups. The validated CV Risk SomaSignal® Test (SST) provides 4-year risk probability of MACE allowing for timely assessment of risk, but the shorter timescale makes comparison to 10-year PCE risk less intuitive.